Biogen has completed its $5.6 billion acquisition of Apellis Pharmaceuticals, a strategic move to bolster its drug pipeline, particularly with the transition of its candidate diranersen into Phase 3 trials. The company reported a strong start to 2026, achieving $2.48 billion in revenue and an adjusted EPS of $3.57, exceeding expectations. Despite some setbacks, including the discontinuation of a Parkinson's drug, Biogen is optimistic about enhanced innovation and competitiveness following the acquisition.
“Biogen $BIIB · is a best performing S&P 500 stock · today · true”
“Biogen · has completed its acquisition of · Apellis Pharmaceuticals”
“Biogen · moved its first-in-class drug candidate · diranersen · into Phase 3 trials”
“Biogen Inc. · completed · acquisition of Apellis Pharmaceuticals, Inc. · $5.3 billion”
“Biogen · reported · Q1 2026 adjusted EPS · $3.57”
“Biogen · reported · revenue · $2.48 billion”
“Biogen · raised · full-year 2026 non-GAAP EPS guidance · between $14.25 and $15.25”
“Biogen · completed · acquisition of Apellis Pharmaceuticals · $5.3 billion”
“Biogen · recently discontinued · development of BIIB122 · for idiopathic Parkinson's disease”
“Biogen · reported · Q1 2026 revenue · $2.48 billion”
“Biogen · experienced · significant Q1 2026 earnings beat · yes”
“Biogen · acquired · Apellis Pharmaceuticals · $5.3 billion”
